21. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study.
作者: Kirsten Dahl.;Søren Toubro.;Sohan Dey.;Ruben Duque do Vale.;Anne Flint.;Agnes Gasiorek.;Arne Heydorn.;Ania M Jastreboff.;Cassandra Key.;Signe Beck Petersen.;Andreas Vegge.;Kasper Adelborg.
来源: Lancet. 2025年
Amycretin is a novel, unimolecular GLP-1 and amylin receptor agonist. The aim of this study was to investigate the safety, tolerability, pharmacokinetics, and effects on bodyweight of subcutaneous amycretin administered over a treatment period of up to 36 weeks in participants with overweight or obesity.
22. Cerebral palsy.
Cerebral palsy is a lifelong physical disability affecting movement and posture. The motor impairments of cerebral palsy result from non-degenerative brain injuries, brain malformations, and genetic variations, arising from multiple risk factors and causal pathways during preconception, pregnancy, birth, or within the first 2 years of life. Over the past decade, substantial progress in diagnosing, preventing, and managing the condition has transformed treatment approaches. A key discovery is that up to 30% of individuals with CP have a genetic contribution. In high-income countries, the prevalence has decreased by as much as 40%, from 2·1 per 1000 livebirths to 1·6 per 1000 livebirths. However, the prevalence is higher in low-income and middle-income countries. Advances in early diagnosis make identification of cerebral palsy at as early as age 3 months possible, enabling timely, intensive early intervention that improves child and parent outcomes. Additionally, new medical, regenerative, and rehabilitation therapies have emerged, enhancing function and participation. Growing awareness of the health challenges and physical decline faced by adults underscores the need for a lifelong approach. This Seminar highlights the best available evidence and recent progress to help clinicians address key questions identified by individuals with lived experience.
23. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial.
作者: Agnes Gasiorek.;Arne Heydorn.;Sanaz Gabery.;Julie B Hjerpsted.;Katrine Kirkeby.;Thomas Kruse.;Signe B Petersen.;Søren Toubro.;Andreas Vegge.;Cassandra Key.
来源: Lancet. 2025年
GLP-1 receptor agonists and amylin receptor agonists have shown clinically relevant weight loss and glucose-lowering effects in people with overweight, obesity, and type 2 diabetes. Amycretin is a novel, single-molecule GLP-1 receptor and amylin receptor agonist. We aimed to investigate the safety, tolerability, pharmacokinetic properties, and pharmacodynamic effects of single ascending doses (part A) and multiple ascending doses (parts B and C/D) of amycretin in adult participants with overweight or obesity.
25. Current treatment for symptomatic uterine fibroids: available evidence and therapeutic dilemmas.
作者: Noa S de Smit.;Maria E de Lange.;Martijn F Boomsma.;Judith A F Huirne.;Wouter J K Hehenkamp.
来源: Lancet. 2025年
This Review offers an evaluation of current treatments for symptomatic uterine fibroids, including uterine artery embolisation, MRI-guided high-intensity focused ultrasound, laparoscopic radiofrequency ablation, transcervical radiofrequency ablation, ulipristal acetate, and oral gonadotropin-releasing hormone antagonists with add-back therapy. Placing these therapies within the IDEAL (Idea, Development, Exploration, Assessment, And Long-Term Follow-Up) framework and the clinical phases of drug development framework, we highlight key gaps in the evidence such as the lack of head-to-head comparisons with standard care, scarce long-term data, and inadequate consideration of real-world fibroid and patient characteristics. We provide a clear overview, assess the strength of the available evidence, and propose a practical flowchart to help clinicians navigate treatment decisions, ensuring the best care for women with symptomatic fibroids at various stages of therapy development. Insight into these matters equips both patient and clinician with essential information to support the process of shared and fully informed decision making. Importantly, this Review also identifies knowledge gaps that contribute to the specification of the fibroid research agenda.
26. Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE): a phase 3, international, randomised, double-blind, placebo-controlled trial.
作者: Ali T Taher.;Hanny Al-Samkari.;Yesim Aydinok.;Martin Besser.;Audra N Boscoe.;Jayme L Dahlin.;Gonzalo De Luna.;Jeremie H Estepp.;Sarah Gheuens.;Keely S Gilroy.;Andreas Glenthøj.;Ai Sim Goh.;Varsha Iyer.;Antonis Kattamis.;Sandra R Loggetto.;Susan Morris.;Khaled M Musallam.;Kareem Osman.;Paolo Ricchi.;Eduardo Salido-Fiérrez.;Sujit Sheth.;Feng Tai.;Heather Tevich.;Katrin Uhlig.;Rolandas Urbstonaitis.;Vip Viprakasit.;Maria Domenica Cappellini.;Kevin H M Kuo.; .
来源: Lancet. 2025年
Non-transfusion-dependent (NTD) thalassaemia is characterised by ineffective erythropoiesis and haemolytic anaemia, leading to long-term complications, poor quality of life, and early mortality. No oral disease-modifying therapies are approved for β-thalassaemia and no agents are approved for α-thalassaemia. The objective of this study was to evaluate the efficacy and safety of mitapivat, an oral activator of pyruvate kinase, in adults with NTD α-thalassaemia or NTD β-thalassaemia.
28. Estimating the potential malaria morbidity and mortality avertable by the US President's Malaria Initiative in 2025: a geospatial modelling analysis.
作者: Tasmin L Symons.;Jailos Lubinda.;Michael McPhail.;Adam Saddler.;Mauricio van den Berg.;Hunter Baggen.;Yuval Berman.;Sarah Hafsia.;Rubi Jayaseelen.;Punam Amratia.;Annie Browne.;Ewan Cameron.;Camilo Vargas-Ruiz.;Susan F Rumisha.;Nick Golding.;Daniel J Weiss.;Peter W Gething.
来源: Lancet. 2025年405卷10496期2231-2240页
Since its inception in 2005, the US President's Malaria Initiative (PMI) has played a major role in the reductions in malaria morbidity and mortality observed across Africa. With the status of PMI funding and operations currently uncertain, we aimed to quantify the impact that a fully functioning PMI would have on malaria cases and deaths in Africa during 2025.
|